Search clinical trials for: salmeterol xinafoate

Total 407 results

Northwestern University
GlaxoSmithKline

Withdrawn

The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD (AQuOS-COPD)

Chronic Obstructive Pulmonary Disease | Sleep Disorders

United States
Orion Corporation, Orion Pharma

Completed

Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler Products and Seretide Diskus

Asthma

Finland
Taipei Veterans General Hospital, Taiwan
GlaxoSmithKline

Unknown

Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS/LABA Versus LAMA

COPD

Taiwan
University of Milan
Università degli Studi di Ferrara; Fondazione Salvatore Maugeri

Completed

Nitric Oxyde Concentration in Chronic Obstructive Pulmonary Disease Patients - SANOB Study (SANOB)

Chronic Obstructive Pulmonary Disease (COPD)

Italy
Intech Biopharm Ltd.

Completed

Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers With Charcoal Block

Asthma | Chronic Obstructive Pulmonary Disease (COPD)

Taiwan
GlaxoSmithKline

Completed

Clinical Assessment Of GW815SF Salmeterol/Fluticasone Propionate(HFA MDI) In Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-

Bronchial Asthma

Japan
Novartis Pharmaceuticals

Completed

Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.) (INSTEAD)

Chronic Obstructive Pulmonary Disease

Colombia, Italy, Switzerland, Argentina, United Kingdom, Mexico, Netherlands, Malaysia, Spain
Neothetics, Inc

Completed

Dose Ranging Study (RESET)

Periumbilical Subcutaneous Adipose Tissue Reduction

United States
Neothetics, Inc

Completed

Dose-ranging Study (LIPO-102-CL-11)

Abdominal Contour Defects

United States
Novartis Pharmaceuticals

Completed

A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149

Chronic Obstructive Pulmonary Disease

China, Argentina, Taiwan, Chile
Arthur F Gelb MD

Completed

Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange

COPD

United States
GlaxoSmithKline

Completed

WEUSKOP6416: Evaluating Pneumonia in Chronic Obstructive Pulmonary Disease (COPD) Subjects

Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline

Withdrawn

Shortness Of Breath Questionnaire Validation Study

Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline

Withdrawn

A Study in Patients With Moderate Asthma to Compare Pharmacokinetics and Pharmacodynamic Effects of Fluticasone Propionate and Salmeterol Delivered Via the ROTAHALER® Inhaler Relative to the DISKUS® Inhaler

Asthma
Boehringer Ingelheim

Completed

Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Australia, Belgium, Brazil, Bulgaria, China, Denmark, France, Germany, Greece, Hungary, Italy, Netherlands, New Zealand, Philippines, Poland, Russian Federation, South Africa, Spain, Taiwan, Tunisia, Turkey, Ukraine, United Kingdom
Guangzhou Institute of Respiratory Disease

Completed

AMP-BPT and His-BPT for Assessment of Asthma (AMPHis)

Asthma
Novartis Pharmaceuticals

Completed

Efficacy and Safety of QMF149 vs. Salmeterol Xinafoate/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)

COPD

Spain, Germany, Belgium, Poland, South Africa, Australia, Greece, Israel, Sweden, Hong Kong, Thailand, Bulgaria, Singapore, Denmark, Finland, Hungary, Romania, Malaysia
Henan University of Traditional Chinese Medicine

Unknown

Effect of Traditional Chinese Medicine on Outcomes in Patients With Severe / Very Severe COPD

Pulmonary Disease, Chronic Obstructive
University of Florida
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Dose-Response of Salmeterol in Children

Asthma

United States
Boehringer Ingelheim

Completed

In Vivo Specificity of KUC 7483 CL Co-administered With Bisoprolol, Propranolol, and Acipimox in Healthy Male Subjects

Healthy
GlaxoSmithKline

Completed

WEUSRTP4850: Phase II: ICS/LABA Use in Pregnancy and Outcomes

Asthma
Boehringer Ingelheim

Completed

Pharmacokinetics of Salmeterol (Serevent®) After Inhalation With Metered Dose Inhaler (MDI) and Diskus® in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Relative Bioavailability of Tiotropium and Salmeterol After Inhalation of a Fixed Combined Dose Compared to Monocomponents in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetics of Salmeterol Via HandiHaler® in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Efficacy, Pharmacokinetics and Safety Comparison of Salmeterol Inhalation Powder Administered Via the HandiHaler® 2 and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Free Combinations of Tiotropium Inhalation Powder Capsule + Salmeterol Metered Dose Inhaler, Tiotropium Inhalation Powder Capsule and Salmeterol Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Salmeterol Inhalation Powder Administered as the Xinafoate Salt From Hard Polyethylene Capsules Via the HandiHaler® 2, and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
University of Chicago
GlaxoSmithKline

Completed

A Pilot Study of the Mechanism of Synergism Between FP and Salmeterol in Preventing COPD Exacerbations

Pulmonary Disease, Chronic Obstructive

United States
University of Miami

Withdrawn

Effect of an Inhaled Glucocorticoid-long-acting Beta Adrenergic Agonist on Endothelial Function in COPD

COPD

United States
GlaxoSmithKline

Completed

Special Drug Use Investigation for ADOAIR Metered-dose Inhaler (Pediatric)

Asthma
Boehringer Ingelheim

Completed

Efficacy and Safety of Tiotropium Compared to Salmeterol and Placebo in Patients With Chronic Obstructive Bronchitis (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Multiple Dose Comparison of Tiotropium Inhalation Capsules, Salmeterol Inhalation Aerosol and Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim
Pfizer

Completed

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II

Asthma

United States, Brazil, China, Colombia, Germany, India, Japan, Mexico, Peru, Poland, Romania
Boehringer Ingelheim
Pfizer

Completed

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I

Asthma

United States, Brazil, China, Guatemala, India, Japan, Latvia, Mexico, Peru, Poland, Russian Federation
Boehringer Ingelheim

Completed

Efficacy and Safety Comparison of Steroid or Placebo in Combination With Salmeterol and Tiotropium in COPD

Pulmonary Disease, Chronic Obstructive

Belgium, Denmark, Germany, Netherlands
Almirall, S.A.

Completed

A Single-dose, Randomised, Crossover, Placebo-controlled Study Assessing Two Fixed-dose Combinations of Inhaled Long-acting Beta-agonist and Corticosteroid

Asthma

Germany, United Kingdom
Boehringer Ingelheim

Completed

Tiotropium and Salmeterol PK Study in COPD Patients

Pulmonary Disease, Chronic Obstructive

Belgium, Netherlands
McGill University Health Centre/Research Institute...
GlaxoSmithKline

Completed

Strategy for Early Treatment of Exacerbations in COPD: Standing Prescriptions of Advair With a Written Action Plan in the Event of an Exacerbation

Chronic Obstructive Pulmonary Disease | COPD

Canada
GlaxoSmithKline

Completed

Effects of Salmeterol on Autonomic Nervous System (ESAN)

Pulmonary Disease, Chronic Obstructive

Germany
GlaxoSmithKline

Completed

Pharmacovigilance Study to Evaluate Safety of SERETIDE in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Efficacy and Safety of Tiotropium and Salmeterol in Moderate Persistent Asthma Patients Homozygous for B16-Arg/Arg

Asthma

Austria, Belgium, Denmark, Finland, France, Germany, Greece, Italy, Russian Federation, Slovakia, South Africa, Spain, Turkey, United Kingdom
Boehringer Ingelheim
Pfizer

Completed

Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.

Pulmonary Disease, Chronic Obstructive

Austria, Belgium, Bulgaria, Czech Republic, Denmark, Finland, France, Germany, Hungary, Israel, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slovakia, Slovenia, Spain, Turkey, Ukraine, United...
Boehringer Ingelheim

Completed

Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD

Pulmonary Disease, Chronic Obstructive

Austria, Canada, France, Germany, Italy, Russian Federation, Sweden
Novartis Pharmaceuticals

Withdrawn

A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

Chronic Obstructive Pulmonary Disease

Germany, Austria
Boehringer Ingelheim

Completed

Pilot Study Comparing Tiotropium (Spiriva) to Salmeterol (Serevent) Plus Fluticasone (Flixotide) in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

South Africa
Novartis Pharmaceuticals

Withdrawn

A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

Chronic Obstructive Pulmonary Disease

Colombia, India, Belgium, Argentina, Czech Republic
Boehringer Ingelheim

Completed

A Comparison of the Effects of Tiotropium Inhalation qd and Salmeterol Inhalation Bid on Arterial Blood Gases.

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

A Six-week Study Comparing the Efficacy and Safety of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, Netherlands, Denmark, France, South Africa, Austria, Belgium, Sweden
FLUIDDA nv

Completed

Compare the Effects of Seretide® Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients

Asthma

Belgium
GlaxoSmithKline

Completed

Special Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)

Respiratory Disorders

3

Subscribe